צמיחת מכירות משנה לשנה (TTM): Kiniksa Corp (KNSA)

Kiniksa Pharmaceuticals develops treatments for rare immune and cardiovascular pathologies, minimizing risks through a diversified portfolio. The YoY sales growth rate over the last four quarters illustrates revenue dynamics, where 58.10 serves as the base parameter value. However, the implementation of robotic dosing and logistics software is complicated by intense pressure from pharma behemoths capable of rapidly seizing market share.
פילוחי נתונים אנליטיים מרוכזים עבור kiniksa.com (KNSA)

The dynamics of this indicator reflect revenue sensitivity to changes in operating flows by comparing current and prior periods. This metric measures the pace of business expansion, allowing for the identification of sales acceleration or stagnation phases. For Kiniksa Pharmaceuticals (KNSA), the volatility of this value is driven by the specifics of developing drugs for rare pathologies and a dependence on partnerships. Analyzing the annual sales growth rate over a 12-month period helps assess the sustainability of product commercialization.